Develops genetic medicines designed to silence disease-causing genes and replace them with functional genes for people with genetic diseases, including OPMD.
10-K for FY2026, filed Sep 14, 2026Benitec Biopharma Inc. (“Benitec” or the “Company” or in the first person, “we” or “our”) is a clinical-stage biotechnology company focused…View ↗
Our proprietary technology platform is designated as DNA-directed RNA interference, or “ddRNAi”, and “silence and replace.” ddRNAi is…View ↗
Our proprietary silence and replace approach to the treatment of genetic diseases combines RNAi with functional gene replacement to…View ↗
Its product candidates are still in development, so it has not established sales or distribution operations. If products are approved, it plans to use strategic alliances and distribution agreements, and may sell directly in some markets.
10-K for FY2026, filed Sep 14, 2026Sales and MarketingView ↗
8-K, filed Nov 13, 2026
On November 12, 2026, the Board of Directors of the Company approved a resolution changing the Company’s fiscal year-end date from June 30…View ↗
8-K, filed Sep 24, 2026
The Audit Committee appointed EY as the Company’s independent registered public accounting firm for the fiscal year ending June 30, 2027.…View ↗
Loading...